SeekingAlpha News Releases and Press Releases From 07/22/24

2024-07-22 02:59:14 ET The Asia-Pacific equity market were mostly lower as market participants access the central bank’s unexpected policy rate cut to support the economy; markets also weighed US President Joe Biden's decision to end his reelection bid.... Read t...

2024-07-22 02:59:14 ET The Asia-Pacific equity market were mostly lower as market participants access the central bank’s unexpected policy rate cut to support the economy; markets also weighed US President Joe Biden's decision to end his reelection bid.... Read t...

2024-07-22 02:59:14 ET The Asia-Pacific equity market were mostly lower as market participants access the central bank’s unexpected policy rate cut to support the economy; markets also weighed US President Joe Biden's decision to end his reelection bid.... Read t...

2024-07-22 02:59:14 ET The Asia-Pacific equity market were mostly lower as market participants access the central bank’s unexpected policy rate cut to support the economy; markets also weighed US President Joe Biden's decision to end his reelection bid.... Read t...

2024-07-22 02:59:14 ET The Asia-Pacific equity market were mostly lower as market participants access the central bank’s unexpected policy rate cut to support the economy; markets also weighed US President Joe Biden's decision to end his reelection bid.... Read t...

2024-07-22 02:18:13 ET Summary LRGF is a passively managed multifactor ETF that tracks the STOXX U.S. Equity Factor Index. LRGF's returns since the index change in June 2022 have been outstanding, as it has outmaneuvered a few peers and the S&P 500 ETF. LRGF's factor mix i...

2024-07-22 02:05:13 ET Summary Northrop Grumman to report Q2 earnings, with expectations of slowdown in key growth programs and pressure on margins from fixed-cost contracts. Signs of emerging growth areas internationally, with potential for increased contracts in Europe and focus...

2024-07-22 01:50:46 ET Summary Mesoblast is developing two key cellular medicines: rexlemestrocel-L and remestemcel-L, targeting serious diseases. Rexlemestrocel-L is in Phase 3 trials for heart failure and chronic back pain but faces inconsistency in efficacy data. Remestemce...

2024-07-22 01:40:40 ET In an unexpected move, the People’s Bank of China (PBOC) cut its one-year and five-year loan prime rates to record lows of 3.35% and 3.85%, respectively, during July's fixing to bolster the fragile economic recovery. ... Read the full article on Seeking A...

2024-07-22 01:40:40 ET In an unexpected move, the People’s Bank of China (PBOC) cut its one-year and five-year loan prime rates to record lows of 3.35% and 3.85%, respectively, during July's fixing to bolster the fragile economic recovery. ... Read the full article on Seeking A...